IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 161 filers reported holding IMPAX LABORATORIES INC in Q3 2014. The put-call ratio across all filers is 0.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $303,000 | -22.9% | 15,583 | -34.0% | 0.00% | -33.3% |
| Q4 2017 | $393,000 | +58.5% | 23,599 | +173.9% | 0.00% | +50.0% |
| Q2 2016 | $248,000 | -5.3% | 8,615 | +5.2% | 0.00% | 0.0% |
| Q1 2016 | $262,000 | -4.4% | 8,191 | +27.9% | 0.00% | 0.0% |
| Q4 2015 | $274,000 | -6.8% | 6,404 | -23.3% | 0.00% | 0.0% |
| Q3 2015 | $294,000 | +143.0% | 8,351 | +216.9% | 0.00% | +100.0% |
| Q2 2015 | $121,000 | +26.0% | 2,635 | +28.5% | 0.00% | 0.0% |
| Q1 2015 | $96,000 | +47.7% | 2,051 | -0.6% | 0.00% | 0.0% |
| Q4 2014 | $65,000 | +16.1% | 2,063 | -13.0% | 0.00% | – |
| Q3 2014 | $56,000 | -24.3% | 2,370 | -3.3% | 0.00% | -100.0% |
| Q2 2014 | $74,000 | +13.8% | 2,452 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $65,000 | +6.6% | 2,452 | +0.5% | 0.00% | 0.0% |
| Q4 2013 | $61,000 | -64.5% | 2,440 | -70.9% | 0.00% | -50.0% |
| Q3 2013 | $172,000 | +95.5% | 8,389 | +89.5% | 0.00% | +100.0% |
| Q2 2013 | $88,000 | – | 4,428 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 423,161 | $13,406,000 | 7.47% |
| Aravt Global | 2,300,000 | $72,864,000 | 5.43% |
| Slate Path Capital LP | 2,330,000 | $73,814,000 | 5.16% |
| Orbimed Advisors | 6,678,000 | $211,559,000 | 2.02% |
| Iguana Healthcare Management, LLC | 100,000 | $3,168,000 | 1.53% |
| Iguana Healthcare Management, LLC | 100,000 | $3,168,000 | 1.53% |
| Penn Capital Management Company, LLC | 709,045 | $22,463,000 | 0.94% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 250,000 | $7,920,000 | 0.79% |
| NEW AMSTERDAM PARTNERS LLC/NY | 276,169 | $8,749,000 | 0.76% |
| Matarin Capital Management, LLC | 52,932 | $1,676,886,000 | 0.74% |